Physician

Rama Balaraman, M.D.

According to 2025 Medicare claims, Rama Balaraman, M.D. (NPI: 1396709424) practices hematology/oncology in the Ocala, FL market, with the plurality of this provider's patient population coming from Marion, FL. This provider's primary affiliated billing organization is OCALA ONCOLOGY CENTER PL (NPI: 1356300958; TIN: 900336929) and primary practice location at 34474-4445. Balaraman is affiliated with the Primary Care Alliance, LLC (ACO ID: D0010), participating under the REACH model.

Balaraman's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 976 traditional Medicare patients, billed 234,561 HCPCS/CPT codes, and received $3,368,607 in Medicare payments. The top billing code was 80053 (Blood test, comprehensive group of blood chemicals). Part D data shows 1,075 prescription claims across 279 beneficiaries totaling $2,315,226 in drug costs, led by Jakafi (Ruxolitinib Phosphate). DME data shows 17 claims. Open Payments data shows 189 records totaling $511,404. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs have risen steadily, from $1,850,580 to $2,315,226. In contrast, DME billing represents a smaller volume and started with an early spike, then settled into a lower baseline, moving from $7,131 to $614.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	1,031	281,353	$3,471,146
2016	1,170	280,837	$3,721,692
2017	1,193	344,285	$5,021,339
2018	1,104	409,635	$6,531,219
2019	1,146	385,149	$6,340,780
2020	1,009	307,801	$5,195,163
2021	1,034	351,251	$5,553,058
2022	991	294,747	$4,931,026
2023	948	256,465	$4,453,222
2024	976	234,561	$3,368,607

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	275	1,562	$1,850,580
2016	317	1,524	$1,798,712
2017	323	1,467	$1,553,276
2018	333	1,557	$1,684,012
2019	362	1,502	$1,408,674
2020	357	1,338	$1,686,642
2021	311	1,118	$1,962,636
2022	284	1,000	$1,960,129
2023	273	1,020	$2,477,595
2024	279	1,075	$2,315,226

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	130	$5,125
2016	N/R	32	$1,792
2017	N/R	147	$11,166
2018	13	130	$9,163
2019	11	51	$3,609
2020	12	79	$6,884
2021	12	43	$4,645
2022	N/R	N/R	N/R
2023	N/R	12	$2,166
2024	13	17	$3,880

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
80053	Blood test, comprehensive group of blood chemicals	588	1,966	$10
36415	Insertion of needle into vein for collection of blood sample	606	2,984	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	600	3,127	$8
83540	Iron level	316	1,107	$6
83615	Lactate dehydrogenase (enzyme) level	495	1,174	$6

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Jakafi	Ruxolitinib Phosphate	18	540	$303,195
Besremi	Ropeginterferon Alfa-2b-Njft	14	364	$208,369
Brukinsa	Zanubrutinib	14	405	$203,139
Lynparza	Olaparib	15	466	$196,620
Lenalidomide	Lenalidomide	14	350	$181,218

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
L8000	Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type	N	13	17	$3,880

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	164	$5,717	Genentech USA, Inc.
Research Payments	Reported research-related payment or transfer-of-value amount.	25	$505,688	Merck Sharp & Dohme LLC
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Rama Balaraman, M.D.?

Tedicare shows public-source Medicare data for Rama Balaraman, M.D. (NPI 1396709424), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Rama Balaraman, M.D. have ACO affiliation data?

Rama Balaraman, M.D. is shown with ACO affiliation data for Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Rama Balaraman, M.D.?

Rama Balaraman, M.D. is linked to OCALA ONCOLOGY CENTER PL (billing NPI 1356300958) in the available physician profile data.

Does Rama Balaraman, M.D. have Open Payments data?

Rama Balaraman, M.D. has 189 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.